40 “The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers. It’s a revolutionary approach for the treatment of cancer and other serious diseases.We have multiple product candidates in development for a variety of cancers, including Non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).If you are interested in learning more about CAR T cell therapy and the potential treatment process, we break down the process for you and direct you to resources provided by the leading blood cancer advocacy organizations.If you’re interested in a career that pushes the bounds of what is possible and work that has the potential to revolutionize medicine, then we would like to hear from you.Juno CAR T cell therapies are investigational and not FDA approved
Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares).
There is no change to the previously disclosed 2020 financial targets of total net product sales of $19 billion to $20 billion and adjusted EPS greater than $12.50.J.P. THESE DOCUMENTS, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TENDER OFFER AND JUNO STOCKHOLDERS ARE URGED TO READ THEM CAREFULLY WHEN THEY BECOME AVAILABLE. The strategic advantages of this acquisition will include the opportunity to:Celgene will acquire all the outstanding shares of common stock of Juno through a tender offer for $87 per share in cash, or an aggregate of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene.
The transaction was approved by the boards of directors of both companies.Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications. This link will take you to a website to which this These products may not be approved and/or licensed in all countries where this website is accessible. The conference call will be available by webcast on the Investor Relations page of Celgene’s website, You are now leaving www.CELGENE.com, a website provided by Celgene. ET. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno has developed cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Legal counsel for Celgene is Proskauer Rose LLP and Hogan Lovells, and Juno’s legal counsel is Skadden, Arps, Slate, Meagher and Flom, LLP.Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Juno Therapeutics Menu Juno Therapeutics Morgan Stanley & Co. LLC is acting as financial advisor to Juno.
Regulatory approval for JCAR017 in the U.S. is expected in 2019 with potential global peak sales of approximately $3 billion.“The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers,” said Mark J. Alles, Celgene’s Chief Executive Officer.
In April 2016, Celgene exercised its option to develop and commercialize the Juno CD19 program outside North America and China.Celgene will host a conference call today, January 22, to discuss the strategic acquisition of Juno Therapeutics at 8 a.m.
We intend to continually push the boundaries of scientific innovation in the treatment of cancers and to humbly meet the inevitable setbacks with ever-more creative approaches, ... You are now leaving Juno Therapeutics.
Juno is developing autologous cellular biologics as an answer to overcoming tumor evasion and potentially eradicating cancer cells. Future. Celgene Corporation Pays Up For Juno Therapeutics Inc. -- The Market Says "Show Me" Celgene pays a huge premium for a 10% stake in Juno Therapeutics as part of a wider deal. It’s an audacious mission—a quest to radically change the course of medicine.
The resulting capital structure will be consistent with Celgene’s historical financial strategy and strong investment grade profile providing the financial flexibility to pursue Celgene’s strategic priorities and take actions to drive post 2020 growth.The acquisition is expected to be dilutive to adjusted EPS (earnings per share) in 2018 by approximately $0.50 and is expected to be incrementally additive to net product sales in 2020. 2019. “Continuing this work will take scientific prowess, manufacturing excellence and global reach. Appendix. Adding to Celgene’s lymphoma program, JCAR017 (lisocabtagene maraleucel; liso-cel) represents a potentially best-in-class CD19-directed CAR T currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Morgan Securities LLC is acting as financial advisor to Celgene on the transaction.